Ulviprubart
Based on 1 Customer Validation
Ulviprubart (ABC-008) is a monoclonal antibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.39%
- No. CAS: 2569434-60-0
- Peso molecular:146.96 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
KLRG1
In Vitro
Ulviprubart (10 µg/mL, 2-8 h) targets Killer cell lectin-like receptor G1 (KLRG1), eliminates self-reactive T cells through the ADCC mechanism mediated by natural killer (NK) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized KLRG1 Protein, Human (His-SUMO, HY-P71607) can bind Ulviprubart. The EC50 for this effect is 16.68 ng/mL. -
Flow Cytometry analysis of Raji cells labelling KLRG1 (red) with Ulviprubart (anti-KLRG1) (HY-P990026). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
No. CAS 2569434-60-0
-
Appearance Liquid
-
Peso molecular 146.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Ulviprubart]
-
Synonyms
ABC-008
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Brady S, et al. Inclusion body myositis: Correcting mitochondfrial and lysosomal autophagy impairment as a potential therapeutic strategy[J]. Autoimmunity Reviews, 2024: 103644. [Content Brief]
[2]. Konry T, et al., Single Cell Droplet-Based Efficacy and Transcriptomic Analysis of a Novel Anti-KLRG1 Antibody for Elimination of Autoreactive T Cells. Res Sq [Preprint]. 2024 Sep 8:rs.3.rs-4745216. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)